KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) Tax Provisions (2017 - 2025)

Historic Tax Provisions for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Q3 2025 value amounting to $4.4 million.

  • Biomarin Pharmaceutical's Tax Provisions fell 8441.52% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $158.9 million, marking a year-over-year increase of 12969.2%. This contributed to the annual value of $114.9 million for FY2024, which is 44930.68% up from last year.
  • As of Q3 2025, Biomarin Pharmaceutical's Tax Provisions stood at $4.4 million, which was down 8441.52% from $57.3 million recorded in Q2 2025.
  • Biomarin Pharmaceutical's Tax Provisions' 5-year high stood at $57.3 million during Q2 2025, with a 5-year trough of -$17.3 million in Q4 2022.
  • Moreover, its 5-year median value for Tax Provisions was $5.9 million (2023), whereas its average is $13.0 million.
  • Its Tax Provisions has fluctuated over the past 5 years, first tumbled by 9950.44% in 2022, then surged by 436488.55% in 2024.
  • Over the past 5 years, Biomarin Pharmaceutical's Tax Provisions (Quarter) stood at -$8.7 million in 2021, then tumbled by 99.5% to -$17.3 million in 2022, then skyrocketed by 93.95% to -$1.0 million in 2023, then soared by 4364.89% to $44.7 million in 2024, then tumbled by 90.11% to $4.4 million in 2025.
  • Its last three reported values are $4.4 million in Q3 2025, $57.3 million for Q2 2025, and $52.4 million during Q1 2025.